Found: 6
Select item for more details and to access through your institution.
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 468, doi. 10.1111/dom.14890
- By:
- Publication type:
- Article
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 94, doi. 10.1111/dom.14551
- By:
- Publication type:
- Article
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Weight History in Clinical Practice: The State of the Science and Future Directions.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2022, v. 327, n. 2, p. 138, doi. 10.1001/jama.2021.23619
- By:
- Publication type:
- Article